ENTRADA THERAPEUTICS INC (TRDA) Stock News

USA - NASDAQ:TRDA - US29384C1080 - Common Stock

8.72 USD

-0.1 (-1.13%)

Last: 11/19/2025, 11:50:01 AM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

TRDA Latest News, Press Relases and Analysis

All

Press Releases

22 hours ago - By: The Motley Fool - Mentions: VKTX SKYE PHVS CAMP ...

5AM Venture Just Dumped Its Viking Stake—Smart Call or Missed Opportunity?

a day ago - By: The Motley Fool - Mentions: MLTX SKYE PHVS CAMP ...

5AM Venture Bails on MoonLake After a Brutal Year: Here’s What Stands Out

13 days ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Reports Third Quarter 2025 Financial Results

22 days ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics to Present at Upcoming Investor Conferences

22 days ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics to Present at Upcoming Investor Conferences

3 months ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant Program

3 months ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant Program

3 months ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

4 months ago - By: Zacks Investment Research - Mentions: BRTX

Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Lags Revenue Estimates

4 months ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Reports Second Quarter 2025 Financial Results

4 months ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Reports Second Quarter 2025 Financial Results

6 months ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

6 months ago - By: Entrada Therapeutics, Inc. - Mentions: BIIB

Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

6 months ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

6 months ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

6 months ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

6 months ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

7 months ago - By: Zacks Investment Research - Mentions: BHST

Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Tops Revenue Estimates

7 months ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Reports First Quarter 2025 Financial Results

7 months ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Reports First Quarter 2025 Financial Results

7 months ago - By: Zacks Investment Research - Mentions: ETON

Eton Pharmaceuticals, Inc. (ETON) Earnings Expected to Grow: What to Know Ahead of Q1 Release

7 months ago - By: Zacks Investment Research - Mentions: VRTX

Analysts Estimate Entrada Therapeutics, Inc. (TRDA) to Report a Decline in Earnings: What to Look Out for

8 months ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

8 months ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

9 months ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

9 months ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

9 months ago - By: Benzinga

FDA Clears Entrada Therapeutics' Early-Stage For Potential Treatment Of Duchenne Muscular Dystrophy

9 months ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44

9 months ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44

10 months ago - By: Entrada Therapeutics, Inc.

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy